Great session and great panel to discuss the ⁦The Lancet⁩ Prostate Cancer Commission. Many thanks to #APCCC24 for featuring prominently. Will be a fantastic launch pad for new initiatives. ⁦The ICR⁩ thelancet.com/pdfs/journals/…

🍇 Is there a role for adjuvant 💊 chemotherapy in resected invasive IPMN?!

🧑‍🧑‍🧒‍🧒 459 pts / 60% adjuvant chemo / 50% gemcitabine alone

🙈 No benefit for survival / recurrence

🧘‍♀️Careful! No RCT data available yet.. what is your practice ?! 🫵

academic.oup.com/bjs/article-ab…

“So I’m backstage with Taylor, and Travis comes up to me and is like - ‘How does it feel to win the Uromigos cup?’”

#UromigosLive24 #SuperbowlOfOncology
#TeamLA : Tanya Dorff Petros Grivas

Join Dr. Zev Wainberg UCLA Health and me for MOASC event Clinical Webinar Series - Gastrointestinal

May 1, 2024

moasc.org/meetinginfo.ph…

Moderated by Cancer at Cedars-Sinai Dr. Andrew Hendifar & #MOASC pres Dr. Lashkari

#esophagealcancer Cedars-Sinai Academic Medicine GI Oncology Now NoStomachForCancer

Hear hear ye!
FDA Approves Second-Line Tislelizumab Monotherapy in Esophageal squamous Cancer

Another anti-PD1 cancernetwork.com/view/fda-appro…

New evidence-based PCF Prostate Cancer Screening Guidelines for Black Men in the U.S. recommend that Black men consider PSA screening between ages 40-45, and screen annually depending on PSA levels and health status. 🧵⬇️

FDA approves lutetium Lu 177 dotatate for pediatric patients 12 years and older with somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETS). fda.gov/drugs/resource…

#OCENewsBurst

Are ICIs safe in pts with solid organ transplant? Multicentre retrospective study Jordi Remon ESMO Open:

- 31pts (98% kidney, 36% NSCLC)
- irAEs➡️ICI stop 12.9%
- rejection rate 25.8% (mono 28% combo 33% p NS)

A privilege to review this paper OncoAlert
sciencedirect.com/science/articl…

🚨New Urine Test for High-Grade #prostatecancer 🚨

MyProstateScore 2.0 (MPS2 and MPS2+)

At 95% sensitivity for GG2:
✨ Can📉 unnecessary biopsies by 35-42%

Negative predictive value:
✨≥GG2 - 95-99%
✨≥GG3 - 99%

👏 Jeff Tosoian, MD, MPH

▶️JAMA Oncology link: tinyurl.com/25yzhfdd…

💊Adding durvalumab plus bevacizumab to TACE in unresectable HCC
EMERALD-1, ASCO GI24
Journal of Clinical Oncology

✅D+B+TACE vs TACE
mPFS: 15.0 vs 8.2 mo, HR: 0.77 (0.61–0.98) p=0.032
❌D+TACE vs TACE
mPFS: 10.0 vs 8.2 mo, HR: 0.94 (0.75–1.19) p=0.638

👉ascopubs.org/doi/10.1200/JC…

⁉️Whether it…

Jun Gong May Cho Proud of your work, Jun. keep it coming!

Thanks Dr. Marwan G. Fakih!

Important new findings from the #ColoCare Study team on #EOCRC & quality of life. Jennifer Ose Anita Peoples, PhD, MPH Dr. Biljana Gigić #epitwitter Huntsman Cancer Institute

Functional #QOL among newly diagnosed early-onset #colorectalcancer by Dr. Oswald et al Moffitt Cancer Center multidisciplinary collaboration as part of the #ColoCare Study

Sheetal Hardikar Victoria Damerell, PhD Nicole Loroña, PhD
Neli Ulrich, PhD

link.springer.com/article/10.100…

OncoAlert Cancer at Cedars-Sinai

Only Jun Gong can do this! Has been writing/publishing dual/triple since fellowship City of Hope Department of Medical Oncology with Dr. Marwan G. Fakih and Sumanta K. Pal, MD, FASCO!

.Jun Gong Cancer at Cedars-Sinai publishing amazing research in JCO Precision Oncology!

Dual publication on JCO Precision Oncology - Jun Gong
National Cancer Institute Journal of Clinical Oncology The ASCO Post

#Cancer #Cancer Research #OncoDaily #Oncology #TreatmentRefractoryTumors #PrecisionOncology

oncodaily.com/49675.html

Jun Gong JCO Precision Oncology National Cancer Institute ECOG-ACRIN Cancer Research Group OncoAlert Cancer at Cedars-Sinai NCI CTEP Clinical Research NCICancerTrials Heather H. Cheng Carlos L. Arteaga, M.D. VJ Oncology Open Oncology OncoDaily 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Congrats - #FGFR1 -3 important potential agnostic biomarker info 🙌🏻!
Sorry that FGFR1 amplifications did not see responses.

What kind of #gastriccancer care barriers do Asian and Hispanic groups face? Dr. Jun Gong Jun Gong of Cedars-Sinai discusses these barriers and solutions. ow.ly/j8C450Rg8Wj

📢New Paper Alert!📢 Erdafitinib Demonstrates Promising Efficacy in FGFR-Altered Solid Tumors: NCI-MATCH Subprotocol K2 Results
Jun Gong Heather H. Cheng Edith Mitchell, M.D. Carlos L. Arteaga, M.D. JCO Precision Oncology National Cancer Institute ECOG-ACRIN Cancer Research Group #OncoDaily

Summary by Amalya Sargsyan

oncodaily.com/49939.html